Cancer metabolism and oxidative stress: Insights into carcinogenesis and chemotherapy via the non-dihydrofolate reductase effects of methotrexate

BBA Clinical

Volumn 3, Issue , 2015, Pages 152-161

  Hess, Joshua A ^a   Khasawneh, Mohamad K ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer metabolism; Methotrexate; Mitochondria; Oxidative stress; Warburg effect

Indexed keywords

ADENOSINE DIPHOSPHATE; ASPARAGINASE; ASPARTATE AMMONIA LIGASE; FOLINIC ACID; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTAMATE AMMONIA LIGASE; GLUTAMATE CYSTEINE LIGASE; GLUTAMINE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE; MALATE DEHYDROGENASE; METHOTREXATE; ORNITHINE DECARBOXYLASE; PHOSPHOGLUCONATE DEHYDROGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN C FOS; PROTEIN C JUN; RIBOSOME PROTEIN; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C RECEPTOR; SUCCINATE DEHYDROGENASE;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESEARCH; CARCINOGENESIS; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CITRIC ACID CYCLE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME INHIBITION; GLUCOSE METABOLISM; HUMAN; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

EID: 84922561073     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.01.006     Document Type: Review

References (107)

1. Hirsch J. An anniversary for cancer chemotherapy. JAMA 2006, 296(12):1518-1520. 10.1001/jama.296.12.1518.
2. A History of Chemotherapy - (Date of access: 12/29/2014). Novogen. http://www.novogen.com/a-history-of-chemotherapy/.
3. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Res. 2008, 68(21):8643-8653. 10.1158/0008-5472.CAN-07-6611.
4. Chabner B.A., Roberts T.G. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5(1):65-72. 10.1038/nrc1529.
5. Sirotnak F.M., Donsbach R.C. The intracellular concentration dependence of antifolate inhibition of DNA synthesis in L1210 leukemia cells. Cancer Res. 1974, 34(12):332-340.
6. Babiak R.M., Campello A.P., Carnieri E.G., Oliveira M.B. Methotrexate: pentose cycle and oxidative stress. Cell Biochem. Funct. 1998, 16(4):283-293. 10.1002/(SICI)1099-0844(1998120)16:4<283::AID-CBF801>3.0.CO;2-E.
7. Akkemik E., Budak H., Ciftci M. Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J. Enzyme Inhib. Med. Chem. 2010, 25(4):476-479. 10.3109/14756360903257900.
8. Akkemik E., Budak H., Ciftci M. Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study. J. Enzyme Inhib. Med. Chem. 2010, 25(6):871-875. 10.3109/14756360903489581.
9. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314.
10. Brand K.A., Hermfisse U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 1997, 11(5):388-395.
11. Uzar E., Koyuncuoglu H.R., Uz E., Yilmaz H.R., Kutluhan S., Kilbas S., Gultekin F. The activities of antioxidant enzymes and the level of malondialdehyde in cerebellum of rats subjected to methotrexate: protective effect of caffeic acid phenethyl ester. Mol. Cell. Biochem. 2006, 291(1-2):63-68. 10.1007/s11010-006-9196-5.
12. Sullivan S.G., Stern A. Glucose metabolism of oxidatively stressed human red blood cells incubated in plasma or medium containing physiologic concentrations of lactate, pyruvate and ascorbate. Biochem. Pharmacol. 1984, 33(9):1417-1421.
13. Medina M.A. Glutamine and cancer. J. Nutr. 2001, 131(9 Suppl.):2539S-2542S. (discussion 2550S-2531S).
14. Cardaci S., Ciriolo M.R. TCA cycle defects and cancer: when metabolism tunes redox state. Int.J. Cell Biol. 2012, 2012:161837. 10.1155/2012/161837.
15. Guppy M., Leedman P., Zu X., Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem. J. 2002, 364(Pt 1):309-315.
16. MacKenzie E.D., Selak M.A., Tennant D.A., Payne L.J., Crosby S., Frederiksen C.M., Watson D.G., Gottlieb E. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol. Cell. Biol. 2007, 27(9):3282-3289. 10.1128/MCB. 01927-06.
17. Snell C.E., Turley H., McIntyre A., Li D., Masiero M., Schofield C.J., Gatter K.C., Harris A.L., Pezzella F. Proline-hydroxylated hypoxia-inducible factor 1alpha (HIF-1alpha) upregulation in human tumours. PLoS One 2014, 9(2):e88955. 10.1371/journal.pone.0088955.
18. Liu W., Shen S.M., Zhao X.Y., Chen G.Q. Targeted genes and interacting proteins of hypoxia inducible factor-1. Int. J. Biochem. Mol. Biol. 2012, 3(2):165-178.
19. Frezza C., Zheng L., Tennant D.A., Papkovsky D.B., Hedley B.A., Kalna G., Watson D.G., Gottlieb E. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One 2011, 6(9):e24411. 10.1371/journal.pone.0024411.
20. Sookoian S., Pirola C.J. Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. World J. Gastroenterol. 2012, 18(29):3775-3781. 10.3748/wjg.v18.i29.3775.
21. Anastasiou D., Cantley L.C. Breathless cancer cells get fat on glutamine. Cell Res. 2012, 22(3):443-446. 10.1038/cr.2012.5.
22. Mohamed A., Deng X., Khuri F.R., Owonikoko T.K. Altered glutamine metabolism and therapeutic opportunities for lung cancer. Clin. Lung cancer 2014, 15(1):7-15. 10.1016/j.cllc.2013.09.001.
23. Des Rosiers C., Di Donato L., Comte B., Laplante A., Marcoux C., David F., Fernandez C.A., Brunengraber H. Isotopomer analysis of citric acid cycle and gluconeogenesis in rat liver. Reversibility of isocitrate dehydrogenase and involvement of ATP-citrate lyase in gluconeogenesis. J. Biol. Chem. 1995, 270(17):10027-10036.
24. Le A., Lane A.N., Hamaker M., Bose S., Gouw A., Barbi J., Tsukamoto T., Rojas C.J., Slusher B.S., Zhang H., Zimmerman L.J., Liebler D.C., Slebos R.J., Lorkiewicz P.K., Higashi R.M., Fan T.W., Dang C.V. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012, 15(1):110-121. 10.1016/j.cmet.2011.12.009.
25. Aydin B. Quercetin prevents methotrexate-induced hepatotoxicity without interfering with methotrexate metabolizing enzymes in liver of mice. J. Appl. Biol. Sci. 2011, 5(2):75-80.
26. Sener G., Eksioglu-Demiralp E., Cetiner M., Ercan F., Sirvanci S., Gedik N., Yegen B.C. L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol. Toxicol. 2006, 22(1):47-60. 10.1007/s10565-006-0025-0.
27. Abraham P., Kolli V.K., Rabi S. Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochem. Funct. 2010, 28(5):426-433. 10.1002/cbf.1676.
28. Tabassum H., Parvez S., Pasha S.T., Banerjee B.D., Raisuddin S. Protective effect of lipoic acid against methotrexate-induced oxidative stress in liver mitochondria. Food Chem. Toxicol. 2010, 48(7):1973-1979. 10.1016/j.fct.2010.04.047.
29. Caetano N.N., Campello A.P., Carnieri E.G., Kluppel M.L., Oliveira M.B. Effect of methotrexate (MTX) on NAD(P)+ dehydrogenases of HeLa cells: malic enzyme, 2-oxoglutarate and isocitrate dehydrogenases. Cell Biochem. Funct. 1997, 15(4):259-264. 10.1002/(SICI)1099-0844(199712)15:4<259::AID-CBF749>3.0.CO;2-D.
30. Kutzenko A.S., Lamzin V.S., Popov V.O. Conserved supersecondary structural motif in NAD-dependent dehydrogenases. FEBS Lett. 1998, 423(1):105-109.
31. Xiang L., Xie G., Liu C., Zhou J., Chen J., Yu S., Li J., Pang X., Shi H., Liang H. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim. Biophys. Acta 2013, 1833(12):2996-3005. 10.1016/j.bbamcr.2013.08.003.
32. Kohanski M.A., Dwyer D.J., Hayete B., Lawrence C.A., Collins J.J. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007, 130(5):797-810. 10.1016/j.cell.2007.06.049.
33. Chabner B.A., Allegra C.J., Curt G.A., Clendeninn N.J., Baram J., Koizumi S., Drake J.C., Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug?. J. Clin. Invest. 1985, 76(3):907-912. 10.1172/JCI112088.
34. Weigand M., Frei E., Graf N., Wiessler M. Comparative analysis of methotrexate polyglutamates in lymphoblast preparations from bone marrow and blood, and the contribution of residual red blood cells. J. Cancer Res. Clin. Oncol. 2000, 126(7):407-411.
35. Synold T.W., Relling M.V., Boyett J.M., Rivera G.K., Sandlund J.T., Mahmoud H., Crist W.M., Pui C.H., Evans W.E. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest. 1994, 94(5):1996-2001. 10.1172/JCI117552.
36. Rubio I.T., Cao Y., Hutchins L.F., Westbrook K.C., Klimberg V.S. Effect of glutamine on methotrexate efficacy and toxicity. Ann. Surg. 1998, 227(5):772-778. (discussion 778-780).
37. Sur P., Fernandes D.J., Kute T.E., Capizzi R.L. L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y. Cancer Res. 1987, 47(5):1313-1318.
38. Panosyan E.H., Grigoryan R.S., Avramis I.A., Seibel N.L., Gaynon P.S., Siegel S.E., Fingert H.J., Avramis V.I. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res. 2004, 24(2C):1121-1125.
39. Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. 2010, 107(16):7455-7460. 10.1073/pnas.1001006107.
40. Gong S.S., Guerrini L., Basilico C. Regulation of asparagine synthetase gene expression by amino acid starvation. Mol. Cell. Biol. 1991, 11(12):6059-6066.
41. Avramis V.I. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res. 2012, 32(7):2423-2437.
42. Rotoli B.M., Uggeri J., Dall'Asta V., Visigalli R., Barilli A., Gatti R., Orlandini G., Gazzola G.C., Bussolati O. Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol. Biochem. 2005, 15(6):281-292. 10.1159/000087238.
43. Mentel M., Martin W. Energy metabolism among eukaryotic anaerobes in light of Proterozoic ocean chemistry. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2008, 363(1504):2717-2729. 10.1098/rstb.2008.0031.
44. Murphy M.P. Modulating mitochondrial intracellular location as a redox signal. Sci. Signal. 2012, 5(242):pe39. 10.1126/scisignal.2003386.
45. Al-Mehdi A.B., Pastukh V.M., Swiger B.M., Reed D.J., Patel M.R., Bardwell G.C., Pastukh V.V., Alexeyev M.F., Gillespie M.N. Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription. Sci. Signal. 2012, 5(231):ra47. 10.1126/scisignal.2002712.
46. Berridge Michael J. Cell signalling biology: module 2 - cell signalling pathways. Biochem. J. 2012, 10.1042/csb0001002.
47. Krasnov G.S., Dmitriev A.A., Snezhkina A.V., Kudryavtseva A.V. Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a therapeutic target. Expert Opin. Ther. Targets 2013, 10.1517/14728222.2013.775253.
48. Yin H., Zhou Y., Zhu M., Hou S., Li Z., Zhong H., Lu J., Meng T., Wang J., Xia L., Xu Y., Wu Y. Role of mitochondria in programmed cell death mediated by arachidonic acid-derived eicosanoids. Mitochondrion 2012, 10.1016/j.mito.2012.10.003.
49. Strydom A., Dickinson M.J., Shende S., Pratico D., Walker Z. Oxidative stress and cognitive ability in adults with Down syndrome. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33(1):76-80. 10.1016/j.pnpbp.2008.10.006.
50. Karamouzis I., Pervanidou P., Berardelli R., Iliadis S., Papassotiriou I., Karamouzis M., Chrousos G.P., Kanaka-Gantenbein C. Enhanced oxidative stress and platelet activation combined with reduced antioxidant capacity in obese prepubertal and adolescent girls with full or partial metabolic syndrome. Horm. Metab. Res. 2011, 43(9):607-613. 10.1055/s-0031-1284355.
51. Danielson P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 2002, 3(6):561-597.
52. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedeberg's Arch. Pharmacol. 2004, 369(1):89-104. 10.1007/s00210-003-0819-z.
53. Hanukoglu I. Antioxidant protective mechanisms against reactive oxygen species (ROS) generated by mitochondrial P450 systems in steroidogenic cells. Drug Metab. Rev. 2006, 38(1-2):171-196. 10.1080/03602530600570040.
54. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., Sutter T.R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 1996, 56(13):2979-2984.
55. Cronstein B.N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 2005, 57(2):163-172. 10.1124/pr.57.2.3.
56. Maddocks O.D., Berkers C.R., Mason S.M., Zheng L., Blyth K., Gottlieb E., Vousden K.H. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013, 493(7433):542-546. 10.1038/nature11743.
57. Gonzalez C.D., Alvarez S., Ropolo A., Rosenzvit C., Gonzalez Bagnes M.F., Vaccaro M.I. Autophagy, Warburg, and Warburg reverse effects in human cancer. Biomed. Res. Int. 2014, 2014:926729. 10.1155/2014/926729.
58. Cui J., Gong Z., Shen H.M. The role of autophagy in liver cancer: molecular mechanisms and potential therapeutic targets. Biochim. Biophys. Acta 2013, 1836(1):15-26. 10.1016/j.bbcan.2013.02.003.
59. Choi K.S. Autophagy and cancer. Exp. Mol. Med. 2012, 44(2):109-120. 10.3858/emm.2012.44.2.033.
60. Carew J.S., Kelly K.R., Nawrocki S.T. Autophagy as a target for cancer therapy: new developments. Cancer Manag. Res. 2012, 4:357-365. 10.2147/CMAR.S26133.
61. Ecker N., Mor A., Journo D., Abeliovich H. Induction of autophagic flux by amino acid deprivation is distinct from nitrogen starvation-induced macroautophagy. Autophagy 2010, 6(7):879-890. 10.4161/auto.6.7.12753.
62. Eng C.H., Yu K., Lucas J., White E., Abraham R.T. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci. Signal. 2010, 3(119):ra31. 10.1126/scisignal.2000911.
63. Barbisan F., Motta Jde R., Trott A., Azzolin V., Dornelles E.B., Marcon M., Algarve T.D., Duarte M.M., Mostardeiro C.P., Unfer T.C., Schott K.L., da Cruz I.B. Methotrexate-related response on human peripheral blood mononuclear cells may be modulated by the Ala16Val-SOD2 gene polymorphism. PLoS One 2014, 9(10):e107299. 10.1371/journal.pone.0107299.
64. Deffieu M., Bhatia-Kissova I., Salin B., Galinier A., Manon S., Camougrand N. Glutathione participates in the regulation of mitophagy in yeast. J. Biol. Chem. 2009, 284(22):14828-14837. 10.1074/jbc.M109.005181.
65. Xi H., Barredo J.C., Merchan J.R., Lampidis T.J. Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKbeta leading to autophagy. Biochem. Pharmacol. 2013, 10.1016/j.bcp.2013.02.037.
66. Wang Q., Liang B., Shirwany N.A., Zou M.H. 2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase. PLoS One 2011, 6(2):e17234. 10.1371/journal.pone.0017234.
67. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25(34):4633-4646. 10.1038/sj.onc.1209597.
68. Karbowski M., Spodnik J.H., Teranishi M., Wozniak M., Nishizawa Y., Usukura J., Wakabayashi T. Opposite effects of microtubule-stabilizing and microtubule-destabilizing drugs on biogenesis of mitochondria in mammalian cells. J. Cell Sci. 2001, 114(Pt 2):281-291.
69. Menon S.G., Sarsour E.H., Spitz D.R., Higashikubo R., Sturm M., Zhang H., Goswami P.C. Redox regulation of the G1 to S phase transition in the mouse embryo fibroblast cell cycle. Cancer Res. 2003, 63(9):2109-2117.
70. Sweet S., Singh G. Changes in mitochondrial mass, membrane potential, and cellular adenosine triphosphate content during the cell cycle of human leukemic (HL-60) cells. J. Cell. Physiol. 1999, 180(1):91-96. 10.1002/(SICI)1097-4652(199907)180:1<91::AID-JCP10>3.0.CO;2-6.
71. Colombo S.L., Palacios-Callender M., Frakich N., Carcamo S., Kovacs I., Tudzarova S., Moncada S. Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(52):21069-21074. 10.1073/pnas.1117500108.
72. Huang R.F., Ho Y.H., Lin H.L., Wei J.S., Liu T.Z. Folate deficiency induces a cell cycle-specific apoptosis in HepG2 cells. J. Nutr. 1999, 129(1):25-31.
73. Goncharova S.A., Frankfurt O.S. Effect of methotrexate on the cell cycle of L1210 leukemia. Cell Prolif. 1976, 9(4):333-340. 10.1111/j.1365-2184.1976.tb01281.x.
74. Tsurusawa M., Niwa, Katano, Fujimoto Methotrexate cytotoxicity as related to irreversible S phase arrest in mouse L1210 leukemia cells. Jpn. J. Cancer Res. 1990, 81:85-90.
75. Ernst P., Killmann S.A. Perturbation of generation cycle of human leukemic myeloblasts in vivo by methotrexate. Blood 1971, 38(6):689-705.
76. Messina J.P., Lawrence D.A. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J. Immunol. 1989, 143(6).
77. Zhang C., Lin M., Wu R., Wang X., Yang B., Levine A.J., Hu W., Feng Z. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(39):16259-16264. 10.1073/pnas.1113884108.
78. Zhang X.D., Qin Z.H., Wang J. The role of p53 in cell metabolism. Acta Pharmacol. Sin. 2010, 31(9):1208-1212. 10.1038/aps.2010.151.
79. Yamada E., Singh R. Mapping autophagy on to your metabolic radar. Diabetes 2012, 61(2):272-280. 10.2337/db11-1199.
80. Cimmino A., Capasso R., Muller F., Sambri I., Masella L., Raimo M., De Bonis M.L., D'Angelo S., Zappia V., Galletti P., Ingrosso D. Protein isoaspartate methyltransferase prevents apoptosis induced by oxidative stress in endothelial cells: role of Bcl-Xl deamidation and methylation. PLoS One 2008, 3(9):e3258. 10.1371/journal.pone.0003258.
81. Dang C.V. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 2010, 70(3):859-862. 10.1158/0008-5472.CAN-09-3556.
82. Cook S.A., Sugden P.H., Clerk A. Regulation of Bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential. Circ. Res. 1999, 85(10):940-949. 10.1161/01.res.85.10.940.
83. Zirath H., Frenzel A., Oliynyk G., Segerstrom L., Westermark U.K., Larsson K., Munksgaard Persson M., Hultenby K., Lehtio J., Einvik C., Pahlman S., Kogner P., Jakobsson P.J., Henriksson M.A. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(25):10258-10263. 10.1073/pnas.1222404110.
84. Pieczenik S.R., Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp. Mol. Pathol. 2007, 83(1):84-92. 10.1016/j.yexmp.2006.09.008.
85. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative, stress 1997.
86. Soltysova A., Altanerova V., Altaner C. Cancer stem cells. Neoplasma 2005, 52(6):435-440.
87. Todaro M., Francipane M.G., Medema J.P., Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010, 138(6):2151-2162. 10.1053/j.gastro.2009.12.063.
88. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006, 66(4):1883-1890. (discussion 1895-1886). 10.1158/0008-5472.CAN-05-3153.
89. Naviaux R.K. Mitochondrial control of epigenetics. Cancer Biol. Ther. 2008, 7(8):1191-1193.
90. Vincent A., Van Seuningen I. On the epigenetic origin of cancer stem cells. Biochim. Biophys. Acta 2012, 1826(1):83-88. 10.1016/j.bbcan.2012.03.009.
91. Ruggiero C., Ehrenshaft M., Cleland E., Stadler K. High-fat diet induces an initial adaptation of mitochondrial bioenergetics in the kidney despite evident oxidative stress and mitochondrial ROS production. Am. J. Physiol. Endocrinol. Metab. 2011, 300(6):E1047-E1058. 10.1152/ajpendo.00666.2010.
92. Rolo A.P., Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 2006, 212(2):167-178. 10.1016/j.taap.2006.01.003.
93. Frye R.E., Delatorre R., Taylor H., Slattery J., Melnyk S., Chowdhury N., James S.J. Redox metabolism abnormalities in autistic children associated with mitochondrial disease. Transl. Psychiatry 2013, 3:e273. 10.1038/tp.2013.51.
94. Taverne Y.J., Bogers A.J., Duncker D.J., Merkus D. Reactive oxygen species and the cardiovascular system. Oxidative Med. Cell. Longev. 2013, 2013:862423. 10.1155/2013/862423.
95. Hwang A.B., Jeong D.E., Lee S.J. Mitochondria and organismal longevity. Curr. Genomics 2012, 13(7):519-532. 10.2174/138920212803251427.
96. Subramaniam S.R., Chesselet M.F. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog. Neurobiol. 2013, 10.1016/j.pneurobio.2013.04.004.
97. Melo A., Monteiro L., Lima R.M., Oliveira D.M., Cerqueira M.D., El-Bacha R.S. Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives. Oxidative Med. Cell. Longev. 2011, 2011:467180. 10.1155/2011/467180.
98. Muller M., Mentel M., van Hellemond J.J., Henze K., Woehle C., Gould S.B., Yu R.Y., van der Giezen M., Tielens A.G., Martin W.F. Biochemistry and evolution of anaerobic energy metabolism in eukaryotes. Microbiol. Mol. Biol. Rev. 2012, 76(2):444-495. 10.1128/MMBR. 05024-11.
99. Ohta S. Molecular hydrogen is a novel antioxidant to efficiently reduce oxidative stress with potential for the improvement of mitochondrial diseases. Biochim. Biophys. Acta 2012, 1820(5):586-594. 10.1016/j.bbagen.2011.05.006.
100. Santidrian A.F., Matsuno-Yagi A., Ritland M., Seo B.B., LeBoeuf S.E., Gay L.J., Yagi T., Felding-Habermann B. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J. Clin. Invest. 2013, 123(3):1068-1081. 10.1172/JCI64264.
101. Seyfried T.N., Flores R., Poff A.M., D'Agostino D.P. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 2013, 10.1093/carcin/bgt480.
102. Mitchison T.J. The proliferation rate paradox in antimitotic chemotherapy. Mol. Biol. Cell 2012, 23(1):1-6. 10.1091/mbc.E10-04-0335.
103. Marullo R., Werner E., Degtyareva N., Moore B., Altavilla G., Ramalingam S.S., Doetsch P.W. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One 2013, 8(11):e81162. 10.1371/journal.pone.0081162.
104. Toyokuni S. Oxidative stress and cancer: the role of redox regulation. Biotherapy 1998, 11(2-3):147-154.
105. Campos C., Guzman R., Lopez-Fernandez E., Casado A. Evaluation of urinary biomarkers of oxidative/nitrosative stress in children with Down syndrome. Life Sci. 2011, 89(17-18):655-661. 10.1016/j.lfs.2011.08.006.
106. Pallardo F.V., Lloret A., Lebel M., d'Ischia M., Cogger V.C., Le Couteur D.G., Gadaleta M.N., Castello G., Pagano G. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: ataxia-telangiectasia, Down syndrome, Fanconi anaemia and Werner syndrome. Biogerontology 2010, 11(4):401-419. 10.1007/s10522-010-9269-4.
107. Sulthana S.M., Kumar S.N., Sridhar M.G., Bhat B.V., Rao K.R. Levels of non enzymatic antioxidants in Down syndrome. Indian J. Pediatr. 2012, 79(11):1473-1476. 10.1007/s12098-012-0795-8.